Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 5/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | PRKDC | P78527 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.41 |
| ▸ | HSPB1 | P04792 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.40 |
| ▸ | TUBB | P07437 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12491675 | 1.00 | ALDH1A1 (0.44) | ALDH1A1TDP1MAPTKDM4ECYP3A4 | |
| SCHEMBL310903 | 0.93 | MAPT (0.45) | ALDH1A1TDP1MAPTKDM4ECYP3A4 | |
| SCHEMBL30936777 | 0.89 | MAPT (0.39) | ALDH1A1TDP1MAPTKDM4ECYP3A4 | |
| SCHEMBL29934878 | 0.86 | ALDH1A1 (0.44) | ALDH1A1TDP1MAPTKDM4ECYP3A4 | |
| SCHEMBL4306952 | 0.86 | ALDH1A1 (0.44) | ALDH1A1TDP1MAPTKDM4ECYP3A4 | |
| Potassium Ion SCHEMBL7698227 | 0.86 | MAPT (0.40) | ALDH1A1TDP1MAPTKDM4ECYP3A4 | |
| SCHEMBL29661436 | 0.85 | ALDH1A1 (0.50) | ALDH1A1TDP1MAPTKDM4ECYP3A4 | |
| SCHEMBL517768 | 0.85 | ALDH1A1 (0.50) | ALDH1A1TDP1MAPTKDM4ECYP3A4 | |
| SCHEMBL31757016 | 0.84 | ALDH1A1 (0.51) | ALDH1A1TDP1MAPTKDM4ECYP3A4 | |
| SCHEMBL4103425 | 0.84 | MAPT (0.49) | ALDH1A1TDP1MAPTKDM4ECYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4612148-A1 | 2-AMINO-PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE AND 7-AMINO-1-PYRIMIDO[4,5-D]PYRIMIDIN-2(1 H)-ONE DERIVATIVES AS EGFR INHIBITORS FOR THE TREATMENT OF CANCER | Cancer Research Technology Limited (GB) | 2025-09-10 | — | — | EP | disclosed |
| WO-2024259216-A1 | QUINOXALINE DERIVED SULFONAMIDES WITH EGFR DEGRADATION ACTIVITIES AND THEIR USES THEREOF | ACCUTAR BIOTECHNOLOGY, INC. (US) | 2024-12-19 | — | — | WO | disclosed |
| WO-2024238566-A2 | PROCESS FOR MANUFACTURING 6-PERFLUOROPHENYL BENZOXAZINONES | ENKO CHEM, INC. (US) | 2024-11-21 | — | — | WO | disclosed |
| EP-4462999-A1 | PROTOPORPHYRINOGEN OXIDASE INHIBITORS | Enko Chem, Inc. (US) | 2024-11-20 | — | — | EP | disclosed |
| EP-4402133-A1 | PROTOPORPHYRINOGEN OXIDASE INHIBITORS | Enko Chem, Inc. (US) | 2024-07-24 | — | — | EP | disclosed |
| WO-2024094963-A1 | 2-AMINO-PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE AND 7-AMINO-1-PYRIMIDO[4,5-D]PYRIMIDIN-2(1 H)-ONE DERIVATIVES AS EGFR INHIBITORS FOR THE TREATMENT OF CANCER | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2024-05-10 | — | — | WO | disclosed |
| US-20230310428-A1 | EGFR INHIBITOR AND PREPARATION METHOD AND USE THEREOF | Hongyun Biotech Co., Ltd. (CN) | 2023-10-05 | — | — | US | disclosed |
| WO-2023137307-A1 | PROTOPORPHYRINOGEN OXIDASE INHIBITORS | ENKO CHEM, INC. (US) | 2023-07-20 | — | — | WO | disclosed |
| US-20230212147-A1 | ALKENYL PYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | Hongyun Biotech Co., Ltd. (CN) | 2023-07-06 | — | — | US | disclosed |
| CN-113717156-B | EGFR inhibitor, preparation method and application thereof | 南京红云生物科技有限公司 | 2023-05-09 | — | — | CN | disclosed |
| EP-4166553-A1 | ALKENYL PYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | Hongyun Biotech Co., Ltd. (CN) | 2023-04-19 | — | — | EP | disclosed |
| WO-2023044364-A1 | PROTOPORPHYRINOGEN OXIDASE INHIBITORS | ENKO CHEM, INC. (US) | 2023-03-23 | — | — | WO | disclosed |
| WO-2023011610-A1 | BENZODIOXANE COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 南京红云生物科技有限公司 | 2023-02-09 | — | — | WO | disclosed |
| CN-115697996-A | Alkenyl pyrimidine compound, preparation method and application thereof | 南京红云生物科技有限公司 | 2023-02-03 | — | — | CN | disclosed |
| WO-2022194269-A1 | NOVEL EGFR DEGRADATION AGENT | 上海齐鲁制药研究中心有限公司 | 2022-09-22 | — | — | WO | disclosed |
| EP-4058435-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE | Genentech, Inc. (US) | 2022-09-21 | — | — | EP | disclosed |
| WO-2022170164-A1 | SULFONAMIDES WITH EGFR INHIBITION ACTIVITIES AND THEIR USE THEREOF | ACCUTAR BIOTECHNOLOGY, INC. (US) | 2022-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230212147-A1 | ALKENYL PYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | WEE1, EGFR, WEE2 | ALDH1A1 1742/4885TDP1 1031/4885MAPT 2939/4885 |
| US-20230310428-A1 | EGFR INHIBITOR AND PREPARATION METHOD AND USE THEREOF | EGFR, ERBB2, ERBB4 | ALDH1A1 3822/4885TDP1 4189/4885MAPT 2177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.